Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBrigham and Women's Hospital
About this trial
The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).
Eligibility criteria
Qualifiers
History of hypertension
Seated systolic BP < 180 mmHg and diastolic < 110 mmHg if on antihypertensives
Seated systolic BP 141-200 mmHg and/or diastolic BP 90-114 mmHg if not on antihypertensives
LVH by echocardiogram
Disqualifiers
Use of MR antagonist (eplerenone, spironolactone, or finerenone) or amiloride (amiloride inhibits ENaC, which is a key mediator of MR's actions) within the past year
Orthostatic hypotension
Major medical illness, including uncontrolled diabetes mellitus (Hemoglobin A1c >7.5)
LV ejection fraction < 40%
Trial design
Treatments tested in this trial
- Eplerenone
- Chlorthalidone
- Potassium
Treatment groups
75 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov